Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 814

1.

Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study.

Pistone T, Ouattara E, Gabillard D, Lele N, Duvignaud A, Cordel H, Malvy D, Bouchaud O, Abgrall S; ANRS VIHVO Study Group.

Travel Med Infect Dis. 2019 Apr 2. pii: S1477-8939(18)30340-5. doi: 10.1016/j.tmaid.2019.03.010. [Epub ahead of print]

PMID:
30951905
2.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery.

Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V.

HIV Med. 2019 May;20(5):353-358. doi: 10.1111/hiv.12732. Epub 2019 Mar 29.

PMID:
30924598
3.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.

Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT’AIDS STUDY GROUP.

BMC Infect Dis. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5.

4.

Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients.

Bastard JP, Couffignal C, Fellahi S, Bard JM, Mentre F, Salmon D, Katlama C, Raffi F, Leport C, Capeau J; ANRS CO, APROCO-COPILOTE Cohort study group.

Diabetes Metab. 2019 Mar 9. pii: S1262-3636(19)30055-2. doi: 10.1016/j.diabet.2019.02.008. [Epub ahead of print]

PMID:
30862472
5.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.

PMID:
30815916
6.

HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥60: a relative survival analysis in the French Dat'AIDS cohort.

Hentzien M, Dramé M, Delpierre C, Allavena C, Cabié A, Cuzin L, Rey D, Pugliese P, Hédelin G, Bani-Sadr F; Dat’AIDS Study Group.

BMJ Open. 2019 Jan 25;9(1):e024841. doi: 10.1136/bmjopen-2018-024841.

7.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group .

J Antimicrob Chemother. 2019 Feb 11. doi: 10.1093/jac/dkz011. [Epub ahead of print]

PMID:
30753724
8.

High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.

Todesco E, Day N, Amiel C, Elaerts S, Schneider V, Roudière L, Hué S, Liotier JY, Bottero J, L'Yavanc T, Ohayon M, Gosset D, Thibault V, Surgers L, Chas J, Akhavan S, Velter A, Katlama C, Kreplak G, Marcelin AG, Valantin MA.

Int J Antimicrob Agents. 2019 Feb 8. pii: S0924-8579(19)30025-1. doi: 10.1016/j.ijantimicag.2019.02.002. [Epub ahead of print]

PMID:
30742957
9.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.

Delagreverie HM, Grude M, Lambert-Niclot S, Nere ML, Jadand C, Leport C, Raffi F, Ghislain M, Goujard C, Meyer L, Calvez V, Katlama C, Flandre P, Barin F, Delaugerre C.

J Antimicrob Chemother. 2019 Jan 23. doi: 10.1093/jac/dkz004. [Epub ahead of print]

PMID:
30690509
10.

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.

Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR; NEAT001/ANRS143 Trial Study Group.

PLoS One. 2019 Jan 28;14(1):e0209911. doi: 10.1371/journal.pone.0209911. eCollection 2019.

11.

Dynamics in HIV-DNA levels over time in HIV controllers.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221.

12.

Caution is needed in interpreting HIV transmission chains by ultradeep sequencing.

Todesco E, Wirden M, Calin R, Simon A, Sayon S, Barin F, Katlama C, Calvez V, Marcelin AG, Hué S.

AIDS. 2019 Mar 15;33(4):691-699. doi: 10.1097/QAD.0000000000002105.

PMID:
30585843
13.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
14.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

15.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.

Cuzin L, Pugliese P, Katlama C, Bani-Sadr F, Ferry T, Rey D, Lourenco J, Bregigeon S, Allavena C, Reynes J, Cabié A; Dat’AIDS Study Group .

J Antimicrob Chemother. 2019 Mar 1;74(3):754-760. doi: 10.1093/jac/dky497.

PMID:
30534993
16.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

17.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group .

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
18.

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Lê MP, Chaix ML, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS-165 DARULIGHT study group.

Br J Clin Pharmacol. 2019 Jan;85(1):277-280. doi: 10.1111/bcp.13796. Epub 2018 Nov 12. No abstract available.

PMID:
30421447
19.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team.

Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.

PMID:
30420123
20.

Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients.

Allavena C, Hanf M, Rey D, Duvivier C, BaniSadr F, Poizot-Martin I, Jacomet C, Pugliese P, Delobel P, Katlama C, Joly V, Chidiac C, Dournon N, Merrien D, May T, Reynes J, Gagneux-Brunon A, Chirouze C, Huleux T, Cabié A, Raffi F; Dat’AIDS study group.

PLoS One. 2018 Sep 21;13(9):e0203895. doi: 10.1371/journal.pone.0203895. eCollection 2018.

Supplemental Content

Loading ...
Support Center